Investors

Company Profile

Ticker:
RTIX

Sector:
Health Products & Services

Industry:
Medical Laboratories & Research

RTI Biologics, Inc., is the leading provider of sterile biological implants for surgeries around the world. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in spine, sports medicine, orthopedic, dental and other surgical specialties.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps. Two such processes, the BioCleanse® Tissue Sterilization Process and the Tutoplast® Sterilization Process, sterilize tissue, are clinically successful and are scientifically proven to address donor-to-recipient disease transmission risk while preserving tissue strength and biocompatibility. These processes have a proven record of more than two million implants distributed with zero incidence of allograft-associated infection.

Analyst Coverage:

• Canaccord Adams – William Plovanic
• Craig-Hallum Capital – Brooks West
• Emerging Growth Equities, Ltd. – Raymond Myers
• Raymond James & Associates – Jayson Bedford
• Roth Capital – Matt Dolan
• Stephens Inc. – Shawn Fitz
• Sidoti & Company – Gregory Brash
• Susquehanna Financial Group – David Turkaly

RTI Biologics is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding RTI Biologics performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of RTI Biologics or its management. RTI Biologics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.